trending Market Intelligence /marketintelligence/en/news-insights/trending/zgvpwgycnjqhhs4osfoyhg2 content esgSubNav
In This List

AbbVie ordered to pay $3M in AndroGel case


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

AbbVie ordered to pay $3M in AndroGel case

AbbVie Inc. has been ordered to pay more than $3 million to Jesse Mitchell, who claimed to have suffered a heart attack because the company misrepresented the risks of AndroGel, Reuters reported March 26.

A federal jury in Chicago stated that the company was not strictly liable and had not falsely marketed the testosterone replacement drug, but noted that it had acted negligently. The jury awarded the Oregon resident $200,000 in compensatory damages and $3 million in punitive damages.

AbbVie, which is facing 4,510 cases across the U.S. over injuries blamed on the drug, expressed its disappointment with the verdict and plans on appealing the decision, Reuters reported, citing a company statement.

In December 2017, U.S. District Judge Matthew Kennelly reversed a $150 million verdict in favor of Mitchell, stating that the findings of the jury that held the company responsible were "logically incompatible."

AbbVie picked up a win in January when a federal jury found AbbVie's AndroGel not liable for the pulmonary embolism of Arizona resident Robert Nolte.

North Chicago, Ill.-based AbbVie faced its first verdict against AndroGel in October 2017, when a jury placed a $140 million penalty to be paid to Jeffrey Konrad, who claims the drug caused him a heart attack. AbbVie has asked Kennelly to scrap this verdict due to inconsistencies during the trial.